salers. The price increases of the wholesalers and the retailer were adjusted by the government. The insurance hoisting engines, 100% of the retail prices usually covering did not load for use up-requiring medicines, had choice however to pay those prices up. Each physician in Germany enjoyed then complete therapeutic freedom, in order to prescribe, what attached product it or they considered. Occasionally - possibly more than occasionally - they did thus under the clashes of interests caused by the sun-dried preferences or rewards, which were given to that on them by the marketing departments pharmaceutical enterprises. No economist could describe this arrangement as correctly more working „free market perhaps, “, because there was no balance energy, whatever to the demand side of this market. Naturally the arrangement was supportable not over the longer run and became in the beginning of the 90's, in favor of the sun-dried national supervision on drug price calculation and - c$vorschreiben abandoned. Furthermore, as Newhouse (2004) has argued convincingly in A recent commentary on the pricing OF pharmaceutical products, into practice, it is impossible tons develop A price policy for pharmaceutical products that is both statically and dynamically efficient. Static efficiency requires that, RK A given POINT in time, price fuel element set equal ton the Inc. rem valley cost OF producing more outputs with A given capacity, read customers willing tons of cover RKs lease thesis Inc. rem valley costs go unserved. However, given the industry's cost structure, RK that price fixed costs (including R D) wants emergency fuel element recovered. It follows that A statically efficient price ipso facto is dynamically inefficient, because dynamic efficiency requires that, more over the long run, added resources flowinto R D and production capacity UP ton the POINT RK which the social benefits more fromfurther expansionwould NO longer more cover the long runincremental cost OF expansion (including R D). As A result OF this inherent conflict between static and dynamic efficiency, all pricing policies for pharmaceutical products into the material world wants fuel element of compromises between thesis two form OF efficiency. Thus far, thesis of compromises have been anything but balanced, even into whatwere considered by pharmaceuticalmanufacturers as “free markets.” Before 1990, for example, pharmaceutical manufacturers selling products operating in A “free, were in Germany believed they, market” there, because the manufacturers were free ton set the prices for their products tons of German wholesalers. The markups OF wholesalers and retailers were regulated by government. Insurance carrier, typically covering 100% OF the retail prices charged for prescription drugs, had NO choice but tons pay those prices. Every physician in Germany then enjoyed complete therapeutic freedom ton prescribe more whatever product he or she deemed appropriate. Occasionally - perhaps more than occasionally - they did so more under conflicts OF interest created by sundry favors or rewards bestowed on them by the marketing department OF pharmaceutical companies. NO economist could possibly describe this arrangement as A properly functioning “free market,” because there which NO countervailing power of whatsoever on that and side OF that market. Naturally, the arrangement which emergency sustainable more over the longer run and which abandoned into the early 1990s, in favor OF sundry government control on drug pricing and prescribing. ]]>